DE69433935D1 - Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen - Google Patents

Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen

Info

Publication number
DE69433935D1
DE69433935D1 DE69433935T DE69433935T DE69433935D1 DE 69433935 D1 DE69433935 D1 DE 69433935D1 DE 69433935 T DE69433935 T DE 69433935T DE 69433935 T DE69433935 T DE 69433935T DE 69433935 D1 DE69433935 D1 DE 69433935D1
Authority
DE
Germany
Prior art keywords
dna
ligand
receptors
drugs
interrupt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433935T
Other languages
English (en)
Inventor
Lawrence B Hendry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69433935D1 publication Critical patent/DE69433935D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Computing Systems (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Library & Information Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69433935T 1993-11-26 1994-11-28 Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen Expired - Lifetime DE69433935D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15868993A 1993-11-26 1993-11-26
PCT/US1994/013765 WO1995014791A1 (en) 1993-11-26 1994-11-28 Design of drugs involving receptor-ligand-dna interactions

Publications (1)

Publication Number Publication Date
DE69433935D1 true DE69433935D1 (de) 2004-09-09

Family

ID=22569263

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433935T Expired - Lifetime DE69433935D1 (de) 1993-11-26 1994-11-28 Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen

Country Status (8)

Country Link
US (5) US5705335A (de)
EP (1) EP0740708B1 (de)
JP (1) JPH09505603A (de)
AT (1) ATE272719T1 (de)
AU (1) AU1297995A (de)
CA (1) CA2177388A1 (de)
DE (1) DE69433935D1 (de)
WO (1) WO1995014791A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933366B2 (en) * 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6040137A (en) * 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US5978740A (en) * 1995-08-09 1999-11-02 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them
WO1997026277A2 (en) 1996-01-22 1997-07-24 Creative Biomolecules, Inc. Morphogen analogs and methods for producing them
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
US6528271B1 (en) * 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
ATE219847T1 (de) 1997-09-05 2002-07-15 Accelrys Inc Interaktionsmodellierung mit atomaren parametern und anisotropischer dipol-polarisierbarkeit
WO1999028347A1 (en) * 1997-11-27 1999-06-10 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to igf receptor
AU3901099A (en) * 1998-05-12 1999-11-29 Isis Pharmaceuticals, Inc. Characterization of interactions between molecular interaction sites of rna and ligands therefor
AUPP380498A0 (en) * 1998-05-29 1998-06-25 Biomolecular Research Institute Limited Egf receptor agonists and antagonists
US20020035459A1 (en) * 1998-09-14 2002-03-21 George M. Grass Pharmacokinetic-based drug design tool and method
KR100303263B1 (ko) * 1998-10-13 2001-12-01 조양호 벡터를이용한rna분자이차구조의시각화방법
US6298259B1 (en) 1998-10-16 2001-10-02 Univ Minnesota Combined magnetic resonance imaging and magnetic stereotaxis surgical apparatus and processes
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6343257B1 (en) * 1999-04-23 2002-01-29 Peptor Ltd. Identifying pharmacophore containing combinations of scaffold molecules and substituents from a virtual library
US6969763B1 (en) 1999-05-12 2005-11-29 Isis Pharmaceuticals, Inc. Molecular interaction sites of interleukin-2 RNA and methods of modulating the same
US20030083483A1 (en) * 1999-05-12 2003-05-01 Ecker David J. Molecular interaction sites of vimentin RNA and methods of modulating the same
AU2001250955A1 (en) * 2000-03-23 2001-10-03 California Institute Of Technology Method and apparatus for predicting ligand binding interactions
WO2002041184A1 (fr) * 2000-11-14 2002-05-23 Kyorin Pharmaceutical Co., Ltd. Procede de recherche d'un nouveau compose tete de serie
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
US7133783B2 (en) 2000-12-09 2006-11-07 The Regents Of The University Of California X-ray crystal structures of functional ribosome complexes containing transfer RNA and model messenger RNAs and methods of use
US20030162219A1 (en) * 2000-12-29 2003-08-28 Sem Daniel S. Methods for predicting functional and structural properties of polypeptides using sequence models
US20030013137A1 (en) * 2001-03-13 2003-01-16 Barak Larry S. Automated methods of detecting receptor activity
AU2002305274A1 (en) * 2001-04-27 2002-11-11 The General Hospital Corporation 3-structure of a whole integrin $g(a)v$g(b)3 extracellular region and uses therefor
WO2004010243A2 (en) * 2001-10-23 2004-01-29 Pharmacogenetics Development Company, Inc. Systems and methods for rapid evaluation and design of molecules for predicted biological activity
US20040067512A1 (en) * 2001-11-09 2004-04-08 Neurogenetics, Inc. Single nucleotide polymorphisms and mutations on Alpha-2-Macroglobulin
AU2002364894A1 (en) * 2001-11-09 2003-06-30 Neurogenetics, Inc. Single nucleotide polymorphisms and mutations on alpha-2-macroglobulin
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
AU2003231879A1 (en) * 2002-05-28 2003-12-12 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
EP1558737A4 (de) 2002-10-18 2008-06-11 Lg Life Sciences Ltd Mit krebserkrankungen assoziierte genfamilien
CA2504334A1 (en) * 2002-10-30 2004-05-21 Galileo Pharmaceuticals, Inc. Identifying therapeutic compounds based on their physical-chemical properties
JP2007516157A (ja) * 2003-02-06 2007-06-21 トリペップ アクチ ボラゲット グリコシル化された抗原／抗体又はリガンド／受容体特異性交換体
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
JP2006522135A (ja) * 2003-03-31 2006-09-28 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド 喘息およびアレルギーの処置のための両性イオン免疫調節剤
WO2006002299A2 (en) * 2004-06-22 2006-01-05 Sarnoff Corporation Method and apparatus for recognizing 3-d objects
US20060052943A1 (en) * 2004-07-28 2006-03-09 Karthik Ramani Architectures, queries, data stores, and interfaces for proteins and drug molecules
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
KR100954322B1 (ko) 2006-06-14 2010-04-21 주식회사 엘지생명과학 췌장암과 관련된 신규한 ｌｂｆｌ313 유전자
US20090092631A1 (en) * 2007-03-26 2009-04-09 Tripep Ab Glycosylated specificity exchangers that induce an antibody dependent cellular cytotoxicity (adcc) response
EP2164860A2 (de) * 2007-06-06 2010-03-24 Nationwide Children's Hospital, Inc. Verfahren und zusammensetzungen, die mit viralen fusionsproteinen in zusammenhang stehen
WO2009009493A2 (en) 2007-07-09 2009-01-15 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Aegyptin and uses thereof
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
CN102798708A (zh) * 2012-08-23 2012-11-28 中国科学院长春应用化学研究所 一种检测配体与靶标结合特异性的方法及药物筛选方法
EP3337321A4 (de) 2015-08-19 2019-07-17 President and Fellows of Harvard College Lipidierte psa-zusammensetzungen und verfahren
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461619A (en) * 1981-12-29 1984-07-24 Medical College Of Georgia Research Inst. Method of predicting biological activity of compounds by nucleic acid models
US4705796A (en) * 1986-08-25 1987-11-10 Stereochemical Genetics, Inc. Use of 3-N-phenylacetylamino-2,6-piperidinedione for treatment of neuropsychiatric disorders
US5025388A (en) * 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5238947A (en) * 1990-04-12 1993-08-24 University Of Georgia Research Foundation, Inc. Synthetic piperidinediones with cytostatic activity
AU7742491A (en) * 1990-04-12 1991-11-11 Stereo-Chemical Genetics, Inc. Synthetic piperidinediones with cytostatic activity

Also Published As

Publication number Publication date
WO1995014791A1 (en) 1995-06-01
US5888741A (en) 1999-03-30
EP0740708A1 (de) 1996-11-06
AU1297995A (en) 1995-06-13
CA2177388A1 (en) 1995-06-01
US5888738A (en) 1999-03-30
US6306595B1 (en) 2001-10-23
EP0740708B1 (de) 2004-08-04
US20020064790A1 (en) 2002-05-30
JPH09505603A (ja) 1997-06-03
EP0740708A4 (de) 1999-12-01
US5705335A (en) 1998-01-06
ATE272719T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
DE69433935D1 (de) Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen
DeMarzo et al. Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein.
BG105856A (en) Use of hydroxymatairesinol in cancer prevention
DE69627031D1 (de) Dateiprozessor für die verteilung von multimedia-dateien
EP0776331A4 (de) Struktur höherer ordnung und bindung von peptidnukleinsäuren
EP0908818A3 (de) Verfahren und Gerät zum Durchführen von Bytekodeoptimierung während Pausen
DE60041589D1 (de) Reparieren von anwendungen, die inkompatibel zum betriebssystem sind durch bereitstellung von stubs für api's
EP0907125A3 (de) Verfahren und System zur automatischen Erkennung und Auswahl von aktualisierten Versionen eines Satzes von Dateien
WO2000023887A3 (en) Method and apparatus for automatically optimizing execution of a computer program
MY143582A (en) Antibodies to opgl
PL343245A1 (en) Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
Valentin-Opran et al. Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells.
AU2002337336A1 (en) Two tier paste buffer and display
EP1090294A4 (de) Verfahren um die anwesenheit von krebs in einer probe zu bestimmen durch nachweis der expression eines ssx-gens und peptiden, die von ssx oder ny-eso-1 abgeleitet sind
MY121164A (en) Method and system for automated technical support for computers.
WO2000004152A3 (en) Androgen receptor coactivators
MXPA99011723A (es) Remocion de benceno de corrientes organicas usando ciclodextrinas.
Chen et al. A Heterodimeric Nuclear Protein Complex Binds Two Palindromic Sequences in the Proximal Enhancer of the Human erbB-2 Gene (∗)
MXPA02011906A (es) Ensayo, equipo y procedimiento a base de esferas no lavables.
EP1319089A4 (de) In vitro testverfahren zur bestimmung der immunogenizität eines impfstoffes
Ittel et al. DNA-poly (ADP-ribose) polymerase complex: isolation of the DNA wrapping the enzyme molecule
Braf et al. Faster diagnosis of TTP using new Technoscreen Adamts-13 activity assay
von Depka et al. Altered Angiogenic Gene Expression Profiles in Porcine Von Willebrand Disease
Veselá-Prenosilová Zapiski janycara (Book Review)
AU7269100A (en) Method for indirectly determining the blood-clotting status

Legal Events

Date Code Title Description
8332 No legal effect for de